Aclarion CEO Brent Ness to Attend LSI USA 2026
MWN-AI** Summary
Aclarion, Inc., a healthcare technology firm listed on Nasdaq under the ticker symbols ACON and ACONW, is at the forefront of innovation in addressing chronic low back pain through its proprietary platform, NOCISCAN. The company is leveraging biomarkers and augmented intelligence (AI) algorithms to enhance diagnostic precision for physicians by differentiating painful from non-painful spinal discs. Aclarion's CEO, Brent Ness, is set to attend the LSI USA 2026 conference, a major event for MedTech leaders, innovators, and investors, taking place in Dana Point, California, from March 16-20, 2026.
During the event, Ness will engage in discussions with potential industry partners and investors to explore Aclarion's advancements with its MR spectroscopy platform. NOCISCAN gathers data via Magnetic Resonance Spectroscopy (MRS) from MRI scans and processes this information in the cloud, utilizing proprietary algorithms to analyze biomarkers related to disc pain. This technology represents a critical step toward optimizing treatment for chronic low back pain by providing insights into the specific locations contributing to patients' discomfort.
Aclarion's mission is underscored by its commitment to enhancing clinical outcomes through its innovative SaaS platform, marking a novel approach in the medical field. As the company continues to advance its technologies and seeks to expand its market presence, Ness's participation at LSI USA 2026 signifies Aclarion's proactive engagement in the MedTech community. Stakeholders interested in one-on-one meetings with Ness can arrange a session through the provided contact details.
For further insights on Aclarion and its products, stakeholders are encouraged to visit the company’s website and relevant contact information provided in the press release.
MWN-AI** Analysis
As Aclarion, Inc. (Nasdaq: ACON) prepares for its participation in LSI USA 2026, it's critical for investors to analyze the implications of CEO Brent Ness’s engagement at this high-profile MedTech event. Aclarion's NOCISCAN technology, which utilizes advanced MR spectroscopy and AI algorithms to diagnose chronic low back pain, positions the company at the forefront of an urgent medical need.
The meeting scheduled with various investors and industry partners can be seen as a strategic move, particularly as the company seeks to bolster its visibility and credibility within the healthcare technology landscape. It’s worth noting that chronic low back pain remains a significant burden on healthcare systems globally, representing a lucrative market opportunity. Investors should take this into account, considering how NOCISCAN addresses a fundamental challenge by helping differentiate between painful and non-painful lumbar discs, potentially leading to improved patient outcomes and reduced healthcare costs.
Moreover, Mr. Ness's attendance signals Aclarion's commitment to innovation and collaboration within the MedTech ecosystem. Engaging with potential collaborators at LSI USA provides a platform for Aclarion to attract partnerships that could enhance its research capabilities, product development, and market reach.
However, while the prospects appear promising, investors must remain cautious. Forward-looking statements from the company introduce uncertainty related to regulatory pathways, commercialization strategies, and market adoption rates of their technology. The risk factors outlined in their SEC filings deserve thorough consideration.
In conclusion, while Aclarion presents an intriguing investment opportunity due to its innovative solutions in a high-demand sector, potential and current investors should stay vigilant about the inherent risks and the dynamic nature of the MedTech industry. Keeping a close eye on developments post-LSI USA 2026 will be crucial for making informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BROOMFIELD, Colo., March 12, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that Brent Ness, Chief Executive Officer, will be attending LSI USA 2026, one of the leading conferences of global MedTech innovators, investors, and industry leaders.
During the event, Mr. Ness will meet with investors and potential industry partners to discuss Aclarion’s continued progress advancing NOCISCAN, the company’s proprietary MR spectroscopy platform that leverages AI and biomarkers to help physicians distinguish between painful and non-painful discs in patients suffering from chronic low back pain.
To schedule a 1-on-1 meeting with Mr. Ness, please email: ksmith@pcgadvisory.com.
LSI USA 2026
Dates: March 16-20, 2026
Location: Dana Point, CA
Format: In-person 1x1 Meetings
LSI USA ’26 is a premier event focused on accelerating MedTech and HealthTech innovation, bringing together investors, startups, and industry leaders.
For more News from Aclarion, please visit: Latest News
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email: info@aclarion.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the enrollment of patients in our ongoing clinical trial, the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contacts:
Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com
FAQ**
How does Aclarion Inc. Warrant ACONW align with the company's growth strategy, particularly in expanding the clinical applications of the Nociscan platform for chronic low back pain?
What specific milestones does Aclarion aim to achieve with the Nociscan technology that could influence the performance of Aclarion Inc. Warrant ACONW in the upcoming year?
Can you elaborate on the potential partnerships that Aclarion is seeking at LSI USA 2026, and how they might impact the value of Aclarion Inc. Warrant ACONW?
What are the anticipated regulatory hurdles for Nociscan, and how might these affect investor confidence in Aclarion Inc. Warrant ACONW in the short to medium term?
**MWN-AI FAQ is based on asking OpenAI questions about Aclarion Inc. (NASDAQ: ACON).
NASDAQ: ACON
ACON Trading
-3.81% G/L:
$3.28 Last:
12,772 Volume:
$3.40 Open:
